Vigil Neuroscience price target lowered to $14 from $17 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Vigil Neuroscience (VIGL) to $14 from $17 and keeps a Buy rating on the shares ahead of Vigil planning to share the final analysis from the IGNITE Phase 2 trial from all patients at 12 months in Q2. Vigil might have to demonstrate “robust biomarker data” supporting iluzanebart’s reasonable likelihood to predict clinical benefit for an accelerated approval pathway, the analyst tells investors. The firm revisited its operating expense assumptions beyond 2025, which reduced its price target the analyst noted.